Document is current
Any future updates will be listed below
-
Authors
Urbut, Sarah M. https://orcid.org/0000-0002-1135-9647
Yeung, Ming Wai
Khurshid, Shaan
Cho, So Mi Jemma https://orcid.org/0000-0003-2460-3335
Schuermans, Art https://orcid.org/0000-0001-8146-9692
German, Jakob https://orcid.org/0009-0002-1257-7782
Taraszka, Kodi
Paruchuri, Kaavya https://orcid.org/0000-0003-1228-1674
Fahed, Akl C.
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Trinquart, Ludovic
Parmigiani, Giovanni
Gusev, Alexander https://orcid.org/0000-0002-7980-4620
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL1427)
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 30 May 2024
First Online: 7 June 2024
Competing interests
: During the course of the project, M.W.Y. became an employee and stock owner of GSK. A.C.F. is co-founder of Goodpath. PTE reports personal fees from Bayer AG, Novartis, and MyoKardia. GP holds equity in Phaeno Biotechnologies, is on the SAB of RealmIDX and currently consults for Delphi Diagnostics. P.N. reports research grants from Allelica, Apple, Amgen,Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The remaining authors declare no competing interests.
